IP Library › Granted Patent US 12,274,747
Granted Patent B2
US 12,274,747 · App. 17/587,501 · Granted Apr 15, 2025

Compositions and methods for treating cytokine release syndrome

Inventors: Kara Olson (White Plains, NY); Olga Sineshchekova (Pleasantville, NY); Eric Smith (New York, NY); Chia-Yang Lin (Scarsdale, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K39/3955A61K35/17A61K38/1774A61K39/39558A61P35/00A61P37/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,747
App. No.
17/587,501
Granted
Apr 15, 2025
Kind
B2
Abstract

The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.

Claims (39)

1. A method of treating cancer and inhibiting cytokine release syndrome in a subject, comprising conjointly administering to the subject:

(a) a multi-specific antigen binding molecule comprising a first antigen-binding domain that specifically binds to CD3 and a second antigen-binding domain that specifically binds to a tumor antigen; and

(b) a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist, wherein the CD40 antagonist is an antibody or antigen-binding fragment thereof.

2. The method of claim 1 , wherein the multi-specific antigen binding molecule is a bispecific or a tri-specific antigen binding molecule.

3. The method of claim 2 , wherein the multi-specific antigen binding molecule is a tri-specific antigen binding molecule, and the tri-specific antigen binding molecule further comprises a third antigen-binding domain that specifically binds an additional T cell antigen or an additional tumor antigen.

4. The method of claim 3 , wherein the third antigen-binding domain specifically binds CD28.

5. The method of claim 1 , wherein the tumor antigen is selected from CD19, CD123, STEAP2, CD20, SSTR2, CD38, STEAP1, 5T4, ENPP3, PSMA, MUC16, GPRC5D, and BCMA.

6. The method of claim 1 , wherein the multi-specific antigen binding molecule comprises a multi-specific antibody or antigen-binding fragment thereof.

7. The method of claim 1 , wherein the multi-specific antigen binding molecule is selected from a bispecific CD3×CD19 antibody, a bispecific CD3×GPRC5D antibody, a bispecific CD3×CD123 antibody, a bispecific CD3×STEAP2 antibody, a bispecific CD3×CD20 antibody, a bispecific CD3×SSTR 2 antibody, a bispecific CD3×CD38 antibody, a bispecific CD3×STEAP1 antibody, a bispecific CD3×5T4 antibody, a bispecific CD3×ENPP3 antibody, a bispecific CD3×MUC16 antibody, a bispecific CD3×BCMA antibody, a bispecific CD3×PSMA antibody, and a trispecific CD3×CD28×CD38 antibody.

8. The method of claim 1 , wherein the method comprises conjointly administering to the subject the multi-specific antigen binding molecule and the CD40 antagonist.

9. The method of claim 1 , wherein the method comprises conjointly administering to the subject the multi-specific antigen binding molecule and the CAR-T cell expressing the CD40 antagonist, and wherein the CAR-T cell secretes the CD40 antagonist.

10. The method of claim 9 , wherein the CD40 antagonist is a scFv or Fab.

11. The method of claim 1 , wherein the cytokine release syndrome is inhibited as measured by keeping C-reactive protein (CRP) level below 7 mg/dL, IFN-γ below 75 pg/ml, or IL-10 below 60 pg/ml.

12. A method of inhibiting cytokine release syndrome caused by a multi-specific antigen binding molecule comprising a first antigen-binding domain that specifically binds CD3 and a second antigen-binding domain that specifically binds a tumor antigen in a subject, comprising administering to the subject a CD40 antagonist or a CAR-T cell expressing an CD40 antagonist, wherein the CD40 antagonist is an antibody or antigen-binding fragment thereof.

13. The method of claim 12 , wherein the multi-specific antigen binding molecule is a bispecific or a tri-specific antigen binding molecule.

14. The method of claim 13 , wherein the multi-specific antigen binding molecule is a tri-specific antigen binding molecule, and the tri-specific antigen binding molecule further comprises a third antigen-binding domain that specifically binds an additional T cell antigen or an additional tumor antigen.

15. The method of claim 14 , wherein the third antigen-binding domain specifically binds CD28.

16. The method of claim 12 , wherein the tumor antigen is selected from CD19, CD123, STEAP2, CD20, SSTR2, CD38, STEAP1, 5T4, ENPP3, PSMA, MUC16, GPRC5D, and BCMA.

17. The method of claim 12 , wherein the multi-specific antigen binding molecule comprises a multi-specific antibody or antigen-binding fragment thereof.

18. The method of claim 12 , wherein the multi-specific antigen binding molecule is selected from a bispecific CD3×CD19 antibody, a bispecific CD3×GPRC5D antibody, a bispecific CD3×CD123 antibody, a bispecific CD3×STEAP2 antibody, a bispecific CD3×CD20 antibody, a bispecific CD3×SSTR 2 antibody, a bispecific CD3×CD38 antibody, a bispecific CD3×STEAP1 antibody, a bispecific CD3×5T4 antibody, a bispecific CD3×ENPP3 antibody, a bispecific CD3×MUC16 antibody, a bispecific CD3×BCMA antibody, a bispecific CD3×PSMA antibody, and a trispecific CD3×CD28×CD38 antibody.

19. The method of claim 12 , wherein the method comprises conjointly administering to the subject the multi-specific antigen binding molecule and the CD40 antagonist.

20. The method of claim 12 , wherein the method comprises conjointly administering to the subject the multi-specific antigen binding molecule and the CAR-T cell expressing the CD40 antagonist, and wherein the CAR-T cell secretes the CD40 antagonist.

21. The method of claim 20 , wherein the CD40 antagonist is a scFv or Fab.

22. The method of claim 12 , wherein the method further comprises identifying a subject that is susceptible to cytokine release syndrome or in need of reduction in cytokine release prior to administering to the subject the CD40 antagonist or the CAR-T cell expressing the CD40 antagonist.

23. A pharmaceutical composition comprising:

(a) a multi-specific antigen binding molecule comprising a first antigen-binding domain that specifically binds CD3 and a second antigen-binding domain that specifically binds a tumor antigen; and

(b) a CD40 antagonist, wherein the CD40 antagonist is an antibody or antigen-binding fragment thereof.

24. The pharmaceutical composition of claim 23 , wherein the multi-specific antigen binding molecule is a bispecific or a tri-specific antigen binding molecule.

25. The pharmaceutical composition of claim 24 , wherein the multi-specific antigen binding molecule is a tri-specific antigen binding molecule, and the tri-specific antigen binding molecule further comprises a third antigen-binding domain that specifically binds an additional T cell antigen or an additional tumor antigen.

26. The pharmaceutical composition of claim 25 , wherein the third antigen-binding domain specifically binds CD28.

27. The pharmaceutical composition of claim 23 , wherein the tumor antigen is selected from CD19, CD123, STEAP2, CD20, SSTR2, CD38, STEAP1, 5T4, ENPP3, PSMA, MUC16, GPRC5D, and BCMA.

28. The pharmaceutical composition of claim 23 , wherein the multi-specific antigen binding molecule comprises a multi-specific antibody or antigen-binding fragment thereof.

29. The pharmaceutical composition of claim 23 , wherein the multi-specific antigen binding molecule is selected from a bispecific CD3×CD19 antibody, a bispecific CD3×GPRC5D antibody, a bispecific CD3×CD123 antibody, a bispecific CD3×STEAP2 antibody, a bispecific CD3×CD20 antibody, a bispecific CD3×SSTR 2 antibody, a bispecific CD3×CD38 antibody, a bispecific CD3×STEAP1 antibody, a bispecific CD3×5T4 antibody, a bispecific CD3×ENPP3 antibody, a bispecific CD3×MUC16 antibody, a bispecific CD3×BCMA antibody, a bispecific CD3×PSMA antibody, and a trispecific CD3×CD28×CD38 antibody.

30. The pharmaceutical composition of claim 23 , further comprising a pharmaceutically acceptable carrier.

31. A method of treating cancer and inhibiting cytokine release syndrome in a subject, comprising administering to the subject a pharmaceutical composition of claim 23 .

32. A method of treating cancer and inhibiting cytokine release syndrome in a subject comprising:

(a) identifying a subject that is susceptible for cytokine release syndrome or in need of reduction in cytokine release; and

(b) administering to the subject a pharmaceutical composition of claim 23 .

33. The method of claim 1 , wherein the method further comprises identifying a subject that is susceptible for cytokine release syndrome or in need of reduction in cytokine release prior to conjointly administering to the subject the multi-specific antigen binding molecule and the CD40 antagonist or the CAR-T cell expressing the CD40 antagonist.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: OLSON, KARA; SINESHCHEKOVA, OLGA; SMITH, ERIC; LIN, CHIA-YANG
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067754/0601 →
Continuity (2)
Provisional Application 63142643 · Jan 28, 2021
Related Publication 20220233690A1 · Jul 28, 2022
References Cited (144)
US 4708871A · Geysen · 1987 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5674492A · Armitage et al. · 1997 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5827642A · Riddell et al. · 1998 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6087329A · Armitage et al. · 2000 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7575923B2 · Dorken et al. · 2009 [cited by applicant]
US 7635472B2 · Kufer et al. · 2009 [cited by applicant]
US 8669352B2 · den Hartog et al. · 2014 [cited by applicant]
US 8716415B2 · Kim et al. · 2014 [cited by applicant]
US 9125893B2 · Endo et al. · 2015 [cited by applicant]
US 9315567B2 · Chang et al. · 2016 [cited by applicant]
US 9598494B2 · Takahashi et al. · 2017 [cited by applicant]
US 9657102B2 · Smith et al. · 2017 [cited by applicant]
US 10787521B2 · Bonvini et al. · 2020 [cited by applicant]
US 20080057070A1 · Long et al. · 2008 [cited by applicant]
US 20110195454A1 · McWhirter et al. · 2011 [cited by applicant]
US 20130191346A1 · Philipp et al. · 2013 [cited by applicant]
US 20140088295A1 · Smith et al. · 2014 [cited by applicant]
US 20140243504A1 · Davis et al. · 2014 [cited by applicant]
US 20160326249A1 · Ng et al. · 2016 [cited by applicant]
US 20170158771A1 · Glennie et al. · 2017 [cited by applicant]
US 20170320947A1 · Moore et al. · 2017 [cited by applicant]
US 20170342160A1 · Mertens et al. · 2017 [cited by applicant]
US 20180118848A1 · Haber et al. · 2018 [cited by applicant]
US 20180222987A1 · Albrecht et al. · 2018 [cited by applicant]
US 20180252727A1 · Garfall et al. · 2018 [cited by applicant]
US 20180305465A1 · Stevens et al. · 2018 [cited by applicant]
US 20190241657A1 · Albrecht et al. · 2019 [cited by applicant]
US 20190263920A1 · Vu et al. · 2019 [cited by applicant]
US 20190284279A1 · Kong et al. · 2019 [cited by applicant]
US 20190336504A1 · Gill et al. · 2019 [cited by applicant]
US 20200024356A1 · Smith et al. · 2020 [cited by applicant]
US 20200102403A1 · Ollier · 2020 [cited by applicant]
US 20200129617A1 · Brownstein et al. · 2020 [cited by applicant]
US 20200140552A1 · Wu et al. · 2020 [cited by applicant]
US 20200172627A1 · Bacac et al. · 2020 [cited by applicant]
US 20200172879A1 · Suri · 2020 [cited by examiner]
US 20200199231A1 · Engelberts et al. · 2020 [cited by applicant]
US 20200277397A1 · Satijn et al. · 2020 [cited by applicant]
US 20200283523A1 · Liu et al. · 2020 [cited by applicant]
US 20200291123A1 · Park et al. · 2020 [cited by applicant]
PH 12010500253B1 · 2017 [cited by examiner]
WO WO2000075348A1 · 2000 [cited by applicant]
WO WO2002011763A1 · 2002 [cited by applicant]
WO WO2002028481A3 · 2003 [cited by applicant]
WO WO2003028809A1 · 2003 [cited by applicant]
WO WO2003029296A1 · 2003 [cited by applicant]
WO WO2003045978A2 · 2003 [cited by applicant]
WO WO2005044854A2 · 2005 [cited by applicant]
WO WO2006073443A2 · 2006 [cited by applicant]
WO WO2007124299A2 · 2007 [cited by applicant]
WO WO2011123489A2 · 2011 [cited by applicant]
WO WO2012055961A1 · 2012 [cited by applicant]
WO WO2012075111A1 · 2012 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by applicant]
WO WO2012129514A1 · 2012 [cited by applicant]
WO WO2013041687A1 · 2013 [cited by applicant]
WO WO2013072406A1 · 2013 [cited by applicant]
WO WO2014047231A1 · 2014 [cited by applicant]
WO WO2014140248A1 · 2014 [cited by applicant]
WO WO2015149077A1 · 2015 [cited by applicant]
WO WO2016036937A1 · 2016 [cited by applicant]
WO WO2016048938A1 · 2016 [cited by applicant]
WO WO2016081490A1 · 2016 [cited by applicant]
WO WO2016086189A2 · 2016 [cited by applicant]
WO WO2016105450A2 · 2016 [cited by applicant]
WO WO2016166629A1 · 2016 [cited by applicant]
WO WO2016196314A1 · 2016 [cited by applicant]
WO WO2017023761A1 · 2017 [cited by applicant]
WO WO2017031104A1 · 2017 [cited by applicant]
WO WO2017040566A1 · 2017 [cited by applicant]
WO WO2017053856A1 · 2017 [cited by applicant]
WO WO2017060242A1 · 2017 [cited by applicant]
WO WO2017087603A1 · 2017 [cited by applicant]
WO WO2017095267A1 · 2017 [cited by applicant]
WO WO2017096368A1 · 2017 [cited by applicant]
WO WO2017097723A2 · 2017 [cited by applicant]
WO WO2017112775A1 · 2017 [cited by applicant]
WO WO2017134134A1 · 2017 [cited by applicant]
WO WO2017210443A1 · 2017 [cited by applicant]
WO WO2017210485A1 · 2017 [cited by applicant]
WO WO2018005706A1 · 2018 [cited by applicant]
WO WO2018017786A2 · 2018 [cited by applicant]
WO WO2018058001A1 · 2018 [cited by applicant]
WO WO2018093821A1 · 2018 [cited by applicant]
WO WO2018067331A9 · 2018 [cited by applicant]
WO WO2018114748A1 · 2018 [cited by applicant]
WO WO2018188612A1 · 2018 [cited by applicant]
WO WO2018217976A1 · 2018 [cited by applicant]
WO WO2018223004A1 · 2018 [cited by applicant]
WO WO2019050521A1 · 2019 [cited by applicant]
WO WO2019075359A1 · 2019 [cited by applicant]
WO WO2019155008A1 · 2019 [cited by applicant]
WO WO2019156565A1 · 2019 [cited by applicant]
WO WO2019191120A1 · 2019 [cited by applicant]
WO WO2019210147A1 · 2019 [cited by applicant]
WO WO2019220369A2 · 2019 [cited by applicant]
WO WO2019224718A2 · 2019 [cited by applicant]
WO WO2019226761A1 · 2019 [cited by applicant]
WO WO2019228406A1 · 2019 [cited by applicant]
WO WO2019232528A1 · 2019 [cited by applicant]
WO WO2019237081A1 · 2019 [cited by applicant]
WO WO2019246356A1 · 2019 [cited by applicant]
WO WO2020006347A1 · 2020 [cited by applicant]
WO WO2020018556A1 · 2020 [cited by applicant]
WO WO2020018820A1 · 2020 [cited by applicant]
WO WO2020025596A1 · 2020 [cited by applicant]
WO WO2020048525A1 · 2020 [cited by applicant]
WO WO2020088608A1 · 2020 [cited by applicant]
WO WO2020092404A1 · 2020 [cited by applicant]
WO WO2020106620A1 · 2020 [cited by applicant]
WO WO2020135335A1 · 2020 [cited by applicant]
WO WO2020144605A1 · 2020 [cited by applicant]
WO WO2020156405A1 · 2020 [cited by applicant]
WO WO2020180726A1 · 2020 [cited by applicant]
WO WO2020191346A1 · 2020 [cited by applicant]
WO WO2022165171A1 · 2022 [cited by applicant]
Chen et al., “A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities,” Clinical and Translational Science, 12(6): 600-608 (2019). [cited by applicant]
Gokbuget et al., “Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia,” Blood, 131(14): 1522-1531 (2018). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/014307 dated Jul. 14, 2022. [cited by applicant]
Li et al., “CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity,” Science Translational Medicine, 11(508): eeax8861 (2019). [cited by applicant]
Xu et al., “Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells,” Cancer Letters, 343(2): 172-178 (2013). [cited by applicant]
Bankert et al., “Induction of an Altered CD40 Signaling Complex by an Antagonistic Human Monoclonal Antibody to CD40,” The Journal of Immunology, 194(9): 4319-4327 (2015). [cited by applicant]
Bensinger et al., “A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma,” British Journal of Haematol… [cited by applicant]
Byrd et al., “Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia,” Leukemia & Lymphoma, 53(11): 15 pages (2012). [cited by applicant]
Fisher et al., “The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjogren's Syndrome: A phase Ila Double-cBlind, Placebo-Controlled Randomized Trial,” 2017 ACR/ARHP Annual … [cited by applicant]
Kahaly et al., “OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves' Hyperthyroidism,” Journal of the Endocrine Society, 3(Supplement1): OR19-6 (2019). [cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood, 124(2): 188-195 (2014). [cited by applicant]
Musselli et al., “BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (Mab): Lessons Learned from an Early Development Program,” 2017 ACR/ARHP Annual Meeting Abstract: Abstract No. 45 (Sep. 18, 2017). [cited by applicant]
Neelapu et al., “Chimeric antigen receptor T-cell therapy—assessment and management of toxicities,” Nature Reviews Clinical Oncology, 15: 47-62 (37 pages)(2018). [cited by applicant]
Neelapu et al., “Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’,” Nature Reviews Clinical Oncology, 15: 3 pages (2018). [cited by applicant]
Perper et al., “Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus,” The Journal of Immunology, … [cited by applicant]
Visvanathan et al., “Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rhuematoid Arthritis (RA),” Arthritis Rheumatol. 68: 1588 (2016). [cited by applicant]
Vornhagen et al., “Cytokine release syndrome,” Journal for Immunotherapy of Cancer, 6: Article 56 pp. 1-14 (2018). [cited by applicant]
Giavridis et al., “CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.” Nature Medicine 24(6) (2018): 731-738. [cited by applicant]
Guo et al., “Focused evaluation of the roles of macrophages in chimeric antigen receptor (Car) T cell therapy associated cytokine release syndrome.” Cancer Biology & Medicine 19 (2022): 333. [cited by applicant]
Piechutta et al., “New emerging targets in cancer immunotherapy: the role of cluster of differentiation 40 (CD40/TNFR5).” ESMO Open 4 (2019): e000510. [cited by applicant]
Vonderheide et al., “Agonistic CD40 antibodies and cancer therapy.” Clin Cancer Res. Mar. 1, 2013; 19(5): 1035-1043. [cited by applicant]
Vonderheide, “CD40 agonist antibodies in cancer immunotherapy.” Annual Review of Medicine 71 (2020): 47-58. [cited by applicant]